Experience With the XIENCE Side-Branch Access Device
Experience With the XIENCE Side-Branch Access Device
Initial human experience with XIENCE SBA continues in Europe as part of a limited operator program at prespecified centers. The results of these initial human implants in terms of device and procedural success will be the focus of future planned publications. Initial physician feedback is currently being assessed and operator observations appear promising thus far.
Given the heterogeneity of bifurcation coronary lesions, the XIENCE SBA may offer versatility in the treatment of anatomic variations of disease. The images above demonstrate use of the XIENCE SBA as part of complex 1- and 2-stent strategies. Device deployment as part of a provisional methodology or even as a simple SB preservation technique, while maintaining MB and SB wire position, may underscore the versatility of this novel device. While images shown here give cause for optimism, further studies to define the role of the XIENCE SBA in the treatment of bifurcation coronary disease and to validate device safety and efficacy are warranted.
Conclusion
Initial human experience with XIENCE SBA continues in Europe as part of a limited operator program at prespecified centers. The results of these initial human implants in terms of device and procedural success will be the focus of future planned publications. Initial physician feedback is currently being assessed and operator observations appear promising thus far.
Given the heterogeneity of bifurcation coronary lesions, the XIENCE SBA may offer versatility in the treatment of anatomic variations of disease. The images above demonstrate use of the XIENCE SBA as part of complex 1- and 2-stent strategies. Device deployment as part of a provisional methodology or even as a simple SB preservation technique, while maintaining MB and SB wire position, may underscore the versatility of this novel device. While images shown here give cause for optimism, further studies to define the role of the XIENCE SBA in the treatment of bifurcation coronary disease and to validate device safety and efficacy are warranted.
Source...